PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 2007 August; 66(8): 1125–1126.
PMCID: PMC1954723

In rheumatoid arthritis, a polymorphism in the HLA‐G gene concurs in the clinical response to methotrexate treatment

We read with interest the editorial “Methotrexate pharmacogenomics” by Kremer, recently published in the Annals of Rheumatic Diseases.1 Several reports have proposed a fundamental role of the folate pathway in the clinical effects of methotrexate (MTX) treatment in rheumatoid arthritis, mainly due to genetic variations in the methylene tetrahydrofolate reductase (MTHFR) gene. The observations by Hughes et al of ethnic differences in the frequencies of single‐nucleotide polymorphisms (SNPs) in the MTHFR coding region suggest possible links between other specific genotypes and MTX response.2

We recently identified an association between the 14 bp deletion/insertion polymorphism in exon 8 at the 3′ untranslated region (UTR) of the HLA‐G gene and the clinical response to MTX treatment in rheumatoid arthritis.3 The HLA‐G antigens are non‐classic MHC class Ib molecules with limited allelic polymorphisms,4 restricted tissue distribution,5,6,7 and alternative splicing mechanisms for mRNA that allow the production of both membrane‐bound and soluble isoforms.8 HLA‐G molecules are associated with the development or persistence of several autoimmune diseases because of their tolerogenic capacity against innate and adaptive responses.7,9 The 14 bp insertion/deletion polymorphism in the HLA‐G gene influences mRNA stability and quantitative protein production. Furthermore, the 14 bp insertion allele (+14 bp) destabilises mRNA and decreases soluble HLA‐G (sHLA‐G) protein production.10

In this study, we showed that MTX can induce the in vitro production of circulating HLA‐G molecules by peripheral blood monocyte cells from healthy subjects and patients with rheumatoid arthritis, with interindividual differences. Moreover, the highest quantitative in vitro production of sHLA‐G molecules was associated with the presence of the deletion (−14/−14 bp) genotype.

To have in vivo confirmation of the pharmacogenetic role of the 14 bp polymorphism in MTX response, we also performed a retrospective study of the genotype distribution in 156 patients with rheumatoid arthritis, who were subdivided into two cohorts on the basis of their clinical response to MTX. The data obtained indicated a significantly higher frequency of the −14/−14 bp genotype in “responder” patients compared with “non‐responders” (χ2 = 6.12; df = 1; p = 0.02 (χ2 test); odds ratio 2.46, 95% CI 1.26 to 4.84; p<0.009).

These results suggest a pharmacogenetic role for the HLA‐G 14 bp polymorphism, and that there is clinical advantage of the −14/−14 bp genotype in response to MTX. The HLA‐G 14 bp polymorphism should be investigated in association with other MTHFR SNPs that predominantly show a role in MTX toxicity.1 The combined analysis of such MTHFR SNPs and the HLA‐G 14 bp polymorphism could help in assessing the likelihood that patients will experience MTX‐related toxicity or benefits.

In conclusion, in rheumatoid arthritis it seems to be important to consider the concurrence of different genetic polymorphisms to help predict the clinical response to MTX treatment.

Abbreviations

MTHFR - methylene tetrahydrofolate reductase

MTX - methotrexate

sHLA‐G - soluble HLA‐G

SNP - single‐nucleotide polymorphism

UTR - untranslated region

References

1. Kremer J M. Metotrexate pharmacogenomics. Ann Rheum Dis 2006. 651121–1123.1123 [PMC free article] [PubMed]
2. Hughes L B, Beasley T M, Patel H, Tiwari H K, Morgan S L, Baggott J E. et al Racial or ethnic differences in allele frequencies of single‐nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis 2006. 651213–1218.1218 [PMC free article] [PubMed]
3. Rizzo R, Rubini M, Govoni M, Padovan M, Melchiorri L, Stignani M. et al HLA‐G 14bp polymorphism regulates the methotrexate response in rheumatoid arthritis. Pharmacogenet Genomics 2006. 9615–623.623 [PubMed]
4. Hylenius S, Andersen A M, Melbye M, Hviid T V. Association between HLA‐G genotype and risk of pre‐eclampsia: a case‐control study using family triads. Mol Hum Reprod 2004. 10237–246.246 [PubMed]
5. Crisa L, McMaster M T, Ishii J K, Fisher S J, Salomon D R. Identification of a thymic epithelial cells subset sharing expression of the class Ib HLA‐G molecule with fetal trophoblast. J Exp Med 1997. 186289–298.298 [PMC free article] [PubMed]
6. Seliger B, Abken H, Ferrone S. HLA‐G and MIC expression in tumors and their role in anti‐tumor immunity. Trends Immunol 2003. 2482–87.87 [PubMed]
7. Fainardi E, Rizzo R, Melchiorri L, Castellazzi M, Paolino E, Tola M R. et al Intrathecal synthesis of soluble HLA‐G and HLA‐I molecules are reciprocally associated to clinical and MRI activity in patients with multiple sclerosis. Mult Scler 2006. 122–12.12 [PubMed]
8. Fujii T, Ishitani A, Geraghty D E. A soluble form of the HLA‐G antigens is encoded by a messenger ribonucleic acid containing intron 4. J Immunol 1994. 1535516–5524.5524 [PubMed]
9. Rizzo R, Mapp C E, Melchiorri L, Maestrelli P, Visentin A, Ferretti S. et al Detective production of soluble HLA‐G molecules by peripheral blood monocytes in patients with asthma. J Allergy Clini Invest 2005. 115508–513.513
10. Rizzo R, Hviid T V F, Stignani M, Balboni A, Grappa M T, Melchiorri L. Relationship between HLA‐G genotype and IL‐10 levels in soluble HLA‐G expression. Immunogenetics 2005. 57172–181.181 [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group